Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness

NCT03005145 · View on ClinicalTrials.gov ↗

Study Summary

The World Health Organization, U.S. Centers for Disease Control and Prevention, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada, and Health Canada have all declared antimicrobial resistance a global threat to health, based on rapidly increasing resistance rates and declining new drug development. Up to 30-50% of antibiotic use is inappropriate, and excessive durations of treatment are the greatest contributor to inappropriate use. Shorter duration treatment (≤7 days) has been shown in meta-analyses to be as effective as longer antibiotic treatment for a range of mild to moderate infections. A landmark trial in critically ill patients with ventilator-associated pneumonia showed that mortality and relapse rates were non-inferior in patients who received 8 vs 15 days of treatment. Similar adequately powered randomized trial evidence is lacking for the treatment of patients with bloodstream infections caused by a wide spectrum of organisms.

Interventions

  • OTHER 7 days of adequate antibiotic treatment
  • OTHER 14 days of adequate antibiotic treatment.

Study Locations (20)

Victoria

  • Ballarat Hospital — Ballarat
  • Bendigo Hospital — Bendigo
  • Casey Hospital — Berwick
  • Monash Medical Centre — Clayton
  • Dandenong Hospital- Monash Health — Dandenong
  • Frankston Hospital — Frankston
  • Peninsula Private Hospital — Langwarrin
  • Cabrini Health — Malvern

New South Wales

  • Bankstown Hospital — Bankstown
  • St Vincent's Hospital — Darlinghurst
  • St. George Hospital — Kogarah
  • John Hunter Hospital — New Lambton Heights
  • Westmead Hospital — Westmead
  • Wollongong Hospital ICU — Wollongong

Western Australia

  • Fiona Stanley Hospital — Murdoch
  • St John of God Hospital — Subiaco

New York

  • NYU School of Medicine — New York

Ohio

  • Cleveland Clinic — Cleveland

Queensland

  • Sunshine Coast University Hospital — Birtinya

Alberta

  • Foothills Hospital — Calgary

Trial Details

FieldValue
Enrollment Target 3,622 participants
Start Date 2017-02-24
Est. Completion 2023-08-03
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03005145

The ClinicalTrials.gov registry entry for NCT03005145 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 3,622 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunnybrook Health Sciences Centre, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions — of which 7 days of adequate antibiotic treatment is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03005145 reports 20 study locations spanning 7 distinct geographic areas — top geographies include Victoria, New South Wales, Western Australia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03005145 about?

NCT03005145 is a clinical study titled "Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness". The World Health Organization, U.S. Centers for Disease Control and Prevention, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada, and Health Canada have all declared antimicrobial resistance a global threat to health, based on rapidly increasing resistance rates and declinin...

What is the current status of trial NCT03005145?

This trial is currently completed. It is a NA study. The enrollment target is 3,622 participants. The study started on 2017-02-24. Estimated completion is 2023-08-03.

What conditions does trial NCT03005145 study?

This clinical trial studies the following conditions: Sepsis, Bacteremia, Critically Ill, Mortality, Intensive Care. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03005145?

The interventions under investigation include: 7 days of adequate antibiotic treatment (OTHER), 14 days of adequate antibiotic treatment. (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03005145?

This trial is sponsored by Sunnybrook Health Sciences Centre, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03005145 being conducted?

This trial has 20 study locations across New York, Ohio, New South Wales, Queensland, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial